A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two fixed doses (200 Mg or 400 Mg) of DVS-233 SR [desvenlafaxine] in adult outpatients with major depressive disorder.
Phase of Trial: Phase III
Latest Information Update: 25 Aug 2009
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Depression; Major depressive disorder
- Focus Therapeutic Use
- 13 Jul 2006 Results have been reported.
- 08 Oct 2005 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History